You are hereWP8: Evidence integration
WP8: Evidence integration
- To integrate the evidence derived from all sources (WP3, WP4, WP5, WP6 and WP7) on QT and TdP liability (arrhythmogenic potential) for each drug.
- To create a ranking of drugs within each therapeutic area regarding QT liability and torsadogenic risk.
- To define subgroups of patients with higher susceptibility because of the presence of concomitant risk factors or an underlying genetic substrate.
- To compare predicted QT liability and TdP liability with actual postmarketing risk.